- Home
- CWEN vs DNLI Comparison
CWEN vs DNLI Comparison
Compare CWEN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- DNLI
- Stock Information
- Founded
- CWEN 2012
- DNLI 2013
- Country
- CWEN United States
- DNLI United States
- Employees
- CWEN N/A
- DNLI N/A
- Industry
- CWEN Electric Utilities: Central
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CWEN Utilities
- DNLI Health Care
- Exchange
- CWEN Nasdaq
- DNLI Nasdaq
- Market Cap
- CWEN 3.1B
- DNLI 3.3B
- IPO Year
- CWEN 2013
- DNLI 2017
- Fundamental
- Price
- CWEN $26.30
- DNLI $21.32
- Analyst Decision
- CWEN Buy
- DNLI Strong Buy
- Analyst Count
- CWEN 8
- DNLI 11
- Target Price
- CWEN $31.63
- DNLI $40.40
- AVG Volume (30 Days)
- CWEN 763.1K
- DNLI 848.7K
- Earning Date
- CWEN 02-20-2025
- DNLI 11-06-2024
- Dividend Yield
- CWEN 6.45%
- DNLI N/A
- EPS Growth
- CWEN 124.49
- DNLI N/A
- EPS
- CWEN 1.04
- DNLI N/A
- Revenue
- CWEN $1,364,000,000.00
- DNLI N/A
- Revenue This Year
- CWEN $9.13
- DNLI N/A
- Revenue Next Year
- CWEN $7.39
- DNLI $420.35
- P/E Ratio
- CWEN $25.39
- DNLI N/A
- Revenue Growth
- CWEN 2.33
- DNLI 204.74
- 52 Week Low
- CWEN $20.63
- DNLI $14.56
- 52 Week High
- CWEN $30.92
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CWEN 38.78
- DNLI 33.87
- Support Level
- CWEN $25.57
- DNLI $20.49
- Resistance Level
- CWEN $26.55
- DNLI $22.21
- Average True Range (ATR)
- CWEN 0.63
- DNLI 1.09
- MACD
- CWEN -0.14
- DNLI -0.16
- Stochastic Oscillator
- CWEN 21.28
- DNLI 14.59
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into conventional power generation, renewables and thermal divisions.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.